Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, United Kingdom.
Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, Camberwell, London, United Kingdom.
PLoS One. 2023 Jul 5;18(7):e0286792. doi: 10.1371/journal.pone.0286792. eCollection 2023.
Up to 50% of autistic people experience co-occurring anxiety, which significantly impacts their quality of life. Consequently, developing new interventions (and/ or adapting existing ones) that improve anxiety has been indicated as a priority for clinical research and practice by the autistic community. Despite this, there are very few effective, evidence-based therapies available to autistic people that target anxiety; and those that are available (e.g., autism adapted Cognitive Behavioural Therapy; CBT) can be challenging to access. Thus, the current study will provide an early-stage proof of concept for the feasibility and acceptability of a novel app-based therapeutic approach that has been developed with, and adapted for, autistic people to support them in managing anxiety using UK National Institute for Health and Care Excellence (NICE) recommended adapted CBT approaches. This paper describes the design and methodology of an ethically approved (22/LO/0291) ongoing non-randomised pilot trial that aims to enrol approximately 100 participants aged ≥16-years with an existing autism diagnosis and mild-to-severe self-reported anxiety symptoms (trial registration NCT05302167). Participants will be invited to engage with a self-guided app-based intervention-'Molehill Mountain'. Primary (Generalised Anxiety Disorder Assessment, Hospital Anxiety and Depression Scale) and secondary outcomes (medication/ service use and Goal Attainment Scaling) will be assessed at baseline (Week 2 +/- 2), endpoint (Week 15 +/- 2) and three follow-ups (Weeks 24, 32 and 41 +/- 4). Participants will also be invited to complete an app acceptability survey/ interview at the study endpoint. Analyses will address: 1) app acceptability/ useability and feasibility (via survey/ interview and app usage data); and 2) target population, performance of outcome measures and ideal timing/ duration of intervention (via primary/ secondary outcome measures and survey/ interview)-with both objectives further informed by a dedicated stakeholder advisory group. The evidence from this study will inform the future optimisation and implementation of Molehill Mountain in a randomised-controlled trial, to provide a novel tool that can be accessed easily by autistic adults and may improve mental health outcomes.
高达 50%的自闭症患者同时患有焦虑症,这显著影响了他们的生活质量。因此,为自闭症患者开发新的干预措施(和/或改编现有措施)以改善焦虑症,已被自闭症患者群体视为临床研究和实践的优先事项。尽管如此,针对焦虑症的自闭症患者有效的、基于证据的治疗方法非常少;而且现有的治疗方法(例如,自闭症适应认知行为疗法;CBT)可能难以获得。因此,目前的研究将为一种新的基于应用程序的治疗方法提供早期概念验证,该方法是为自闭症患者开发和改编的,旨在支持他们使用英国国家卫生与保健优化研究所(NICE)推荐的适应 CBT 方法来管理焦虑症。本文描述了一项经伦理批准(22/LO/0291)的正在进行的非随机试点试验的设计和方法,该试验旨在招募大约 100 名年龄在 16 岁及以上、有自闭症诊断和轻度至重度自我报告的焦虑症状的参与者(试验注册 NCT05302167)。参与者将被邀请使用自我指导的基于应用程序的干预措施-"小山丘"。主要(广泛性焦虑症评估、医院焦虑和抑郁量表)和次要结局(药物/服务使用和目标达成量表)将在基线(第 2 周 +/- 2)、终点(第 15 周 +/- 2)和 3 次随访(第 24、32 和 41 周 +/- 4)时进行评估。参与者还将被邀请在研究终点时完成应用程序可接受性调查/访谈。分析将解决:1)应用程序的可接受性/可用性和可行性(通过调查/访谈和应用程序使用数据);2)目标人群、结局测量的表现和干预的理想时间/持续时间(通过主要/次要结局测量和调查/访谈)-这两个目标都将进一步由一个专门的利益相关者咨询小组提供信息。这项研究的证据将为未来在随机对照试验中优化和实施"Molehill Mountain"提供信息,为自闭症成年人提供一种易于获取的新工具,并可能改善心理健康结局。